TriSalus Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Net Income	-59.04	-47.19	-28.85	-0.71
Depreciation & Amortization	0.7	0.4	0.46	0
Share-Based Compensation	1.4	0.37	0.11	0
Other Operating Activities	6.89	14.11	5.58	0.03
Operating Cash Flow	-50.05	-32.31	-22.7	-0.68
Capital Expenditures	-1.12	-0.79	-1.26	0
Acquisitions	-1	-1	-1	0
Change in Investments	0	0	0	-250
Investing Cash Flow	-2.12	-1.79	-2.26	-250
Share Issuance / Repurchase	0.16	0.09	0.05	245.03
Debt Issued / Paid	-0.09	-0.13	-1.3	-0.18
Other Financing Activities	54.56	13.5	52.02	7.17
Financing Cash Flow	54.63	13.46	50.77	252.01
Net Cash Flow	2.46	-20.64	25.81	1.33
Free Cash Flow	-51.17	-33.1	-23.96	-0.68
Free Cash Flow Margin	-276.41%	-266.97%	-285.14%	-
Free Cash Flow Per Share	-5.45	-106.91	-109.33	-0.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).